- Honduran helicopter crash kills six, including president's sister
- Brazil's Workers Party formalizes support for ex-president Lula
- Foreign minister warns UK cannot become 'vassal state' of EU
- More than half of Britons now want to stay in EU - poll
- An update on winners and losers on the U.S. tax scorecard
- Uber accused of espionage, hacking and bribery in bombshell letter
- Christian Bale and more to salute CNN Heroes
- Destiny 2 Xur Location Guide: Where Is Xur, What Is He Selling? (December 15-18)
- More than half of Britons now want to stay in EU: poll
- Mudslide in southern Chile kills three; 15 others missing
- Odebrecht says dealings with Peru president were legitimate
- U.N. council mulls call for U.S. Jerusalem decision to be withdrawn
- Tillerson confronts North Korea at UN
- Elysee plays down opulence of Macron birthday at Loire chateau
- Argentina fires head of navy over submarine tragedy
- Egyptian presidential hopeful apologizes to arrested supporters
- Argentina fires head of navy after submarine tragedy
- Canadian police probe mysterious deaths of billionaire pharma couple
- Nazareth Christmas celebrations will be held as normal: mayor
- Libyan coast guard rescues more than 250 migrants trying to reach Ital
Sanofi says monitoring outcomes of ongoing dengue vaccination schemes
PARIS (Reuters) - Sanofi (SASY.PA) on Monday said it was monitoring outcomes of ongoing public programs involving its dengue vaccine, Dengvaxia, following the launch of a probe in the Philippines.
The Philippines ordered an investigation into the immunization of more than 730,000 children with the French drugmaker’s product after Sanofi said last week the vaccine should not be recommended for individuals who have not been previously infected by the virus.
“It is important to note that the vast majority of those vaccinated to date live in high endemic settings and, therefore, will have had a prior dengue infection before vaccination,”, Sanofi said in an emailed statement.
Sanofi also said most doses of Dengvaxia, which is available in 11 countries, had been sold in Philippines and Brazil for public health campaigns and added a public vaccination program was “ongoing” in the Brazilian state of Parana.
Reporting by Matthias Blamont; Editing by Ingrid Melander
Our Standards:The Thomson Reuters Trust Principles.